Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | PDE2A | O00408 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27734513 | 0.83 | OPRM1 (0.60) | OPRM1OPRL1SLC6A3SLC6A4PDE2A | |
| SCHEMBL14618820 | 0.81 | HDAC6 (0.47) | OPRM1OPRL1SLC6A3SLC6A4P2RX7 | |
| Hydrochloric Acid SCHEMBL28700235 | 0.79 | HDAC6 (0.46) | OPRM1OPRL1SLC6A3SLC6A4P2RX7 | |
| SCHEMBL16462485 | 0.77 | SLC6A4 (0.41) | OPRM1OPRL1SLC6A3SLC6A4P2RX7 | |
| SCHEMBL28631532 | 0.77 | HDAC3 (0.40) | OPRM1OPRL1PDE2AP2RX7HDAC6 | |
| SCHEMBL16462141 | 0.77 | PDE2A (0.52) | OPRM1OPRL1PDE2AP2RX7 | |
| SCHEMBL5036687 | 0.77 | OPRM1 (0.58) | OPRM1OPRL1HDAC6HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL28932379 | 0.75 | OPRM1 (0.56) | OPRM1OPRL1HDAC6HDAC3HDAC1 | |
| SCHEMBL15056152 | 0.75 | OPRM1 (0.56) | OPRM1OPRL1SLC6A3SLC6A4 | |
| SCHEMBL24397813 | 0.74 | OPRL1 (0.49) | OPRM1OPRL1SLC6A3SLC6A4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207476-B | Indole and azaindole derivatives and their use in neurodegenerative diseases | 默克专利有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2906546-B1 | BENZAMIDES | H LUNDBECK AS (DK) | 2018-01-10 | — | — | EP | disclosed |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | H. LUNDBECK A/S (DK) | 2017-07-20 | — | — | US | disclosed |
| US-9649308-B2 | Benzamide-containing compounds and their use in the treatment of pain | H. LUNDBECK A/S (DK) | 2017-05-16 | — | — | US | disclosed |
| US-20150283134-A1 | Benzamides | MINDIMMUNE THERAPEUTICS, INC. | 2015-10-08 | — | — | US | disclosed |
| EP-2906546-A1 | BENZAMIDES | H. Lundbeck A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-9102591-B2 | Benzamides | H. LUNDBECK A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| WO-2014057078-A1 | BENZAMIDES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | P2RX5, P2RX7, P2RX2 | OPRM1 513/4885OPRL1 158/4885SLC6A3 349/4885 |
| US-20140107340-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | OPRM1 363/4885OPRL1 70/4885SLC6A3 954/4885 |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | P2RX5, P2RX7, P2RX6 | OPRM1 1643/4885OPRL1 832/4885SLC6A3 1126/4885 |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | P2RX5, P2RX7, P2RX6 | OPRM1 1643/4885OPRL1 832/4885SLC6A3 1126/4885 |
| US-20150283134-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | OPRM1 363/4885OPRL1 70/4885SLC6A3 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.